Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial.

Deuter CME, Engelmann K, Heiligenhaus A, Lanzl I, Mackensen F, Ness T, Pleyer U, Stuebiger N, Wilhelm B, Luedtke H, Zierhut M, Doycheva D; MYCUV-IIT02 Study Group.

Br J Ophthalmol. 2018 May;102(5):647-653. doi: 10.1136/bjophthalmol-2017-310156. Epub 2017 Sep 13.

PMID:
28903965
2.

Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.

Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó A, Cuquet Pedragosa J, Ortiz-Santamaria V, Mauri Plana M, Cortés-Hernández J.

Ann Rheum Dis. 2017 Sep;76(9):1575-1582. doi: 10.1136/annrheumdis-2016-210882. Epub 2017 Apr 27.

PMID:
28450313
3.

Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.

Kobashigawa JA, Renlund DG, Gerosa G, Almenar L, Eisen HJ, Keogh AM, Lehmkuhl HB, Livi U, Ross H, Segovia J, Yonan N; ERL2401 Heart Study Investigators.

J Heart Lung Transplant. 2006 Aug;25(8):935-41. Epub 2006 Jun 27.

PMID:
16890114
4.

Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.

Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M.

Transplant Proc. 2009 Nov;41(9):3683-9. doi: 10.1016/j.transproceed.2009.06.183.

PMID:
19917367
5.

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.

Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP.

Lancet. 2016 Sep 17;388(10050):1183-92. doi: 10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16. Erratum in: Lancet. 2016 Sep 17;388(10050):1160.

PMID:
27542302
7.
8.

First experience with enteric-coated mycophenolate sodium (Myfortic) in severe recalcitrant adult atopic dermatitis: an open label study.

van Velsen SG, Haeck IM, Bruijnzeel-Koomen CA, de Bruin-Weller MS.

Br J Dermatol. 2009 Mar;160(3):687-91. doi: 10.1111/j.1365-2133.2008.08978.x. Epub 2008 Dec 11.

PMID:
19120337
9.

Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.

Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M; myPROMS LatAm Study Group.

Transplant Proc. 2005 Mar;37(2):916-9.

PMID:
15848574
10.

Mycophenolate sodium for immunosuppressive treatment in uveitis.

Deuter CM, Doycheva D, Stuebiger N, Zierhut M.

Ocul Immunol Inflamm. 2009 Nov-Dec;17(6):415-9. doi: 10.3109/09273940903137675.

PMID:
20001262
11.
12.

Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis.

Doycheva D, Zierhut M, Blumenstock G, Stuebiger N, Deuter C.

Graefes Arch Clin Exp Ophthalmol. 2011 Aug;249(8):1235-43. doi: 10.1007/s00417-011-1731-8. Epub 2011 Jul 1.

PMID:
21720813
13.

Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.

Budde K, Knoll G, Curtis J, Kahana L, Pohanka E, Seifu Y, Neumayer HH.

Transplant Proc. 2005 Mar;37(2):912-5.

PMID:
15848573
14.

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.

Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Führer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM; European Group on Graves' Orbitopathy (EUGOGO).

Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-8587(18)30020-2. Epub 2018 Jan 31.

PMID:
29396246
15.

Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.

Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.

Transplant Proc. 2004 Mar;36(2 Suppl):524S-527S.

PMID:
15041401
16.

[Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis].

Greiner K, Varikkara M, Santiago C, Forrester JV.

Ophthalmologe. 2002 Sep;99(9):691-4. German.

PMID:
12219257
17.

The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China.

Wang Z, He JJ, Liu XY, Lin B, Zhang L, Geng L, Zheng S.

Immunopharmacol Immunotoxicol. 2015;37(6):508-12. doi: 10.3109/08923973.2015.1096286. Epub 2015 Nov 2.

PMID:
26525836
18.

Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.

Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD.

Transplantation. 2010 Feb 27;89(4):446-51. doi: 10.1097/TP.0b013e3181ca860d.

PMID:
20177347
19.

Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.

Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.

Transplant Proc. 2007 Sep;39(7):2194-6.

PMID:
17889135

Supplemental Content

Support Center